Establishment Labs (NASDAQ:ESTA) Stock Price Down 4.9% - What's Next?

Key Points

• Establishment Labs stock (NASDAQ:ESTA) fell by 4.9% during trading on Wednesday, closing at $38.35 after a decline in trading volume.
• Analysts have mixed opinions on the stock; Citigroup upgraded the price target to $47.00 while Mizuho set a new target of $70.00, indicating a potential for growth.
• The company reported a quarterly revenue increase of 16.1% year-over-year despite posting a higher-than-expected loss of ($0.57) EPS, missing analysts' consensus estimates.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) was down 4.9% during trading on Wednesday . The company traded as low as $38.49 and last traded at $38.35. Approximately 88,327 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 518,060 shares. The stock had previously closed at $40.32.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ESTA. Citigroup raised their price target on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 9th. Mizuho upped their price target on shares of Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Wall Street Zen cut Establishment Labs from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Canaccord Genuity Group started coverage on Establishment Labs in a research report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 target price on the stock. Finally, BTIG Research started coverage on Establishment Labs in a report on Friday, May 16th. They set a "buy" rating and a $62.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $56.50.

Establishment Labs Trading Down 4.2%

The firm's 50-day simple moving average is $41.47 and its 200 day simple moving average is $37.85. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -12.66 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. During the same period last year, the firm posted ($0.62) EPS. Establishment Labs's quarterly revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. Equities analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

Hedge funds have recently made changes to their positions in the stock. Elevation Point Wealth Partners LLC acquired a new position in Establishment Labs during the 1st quarter worth approximately $207,000. New York State Common Retirement Fund bought a new stake in shares of Establishment Labs during the first quarter worth $894,000. Northern Trust Corp increased its holdings in shares of Establishment Labs by 53.9% during the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock worth $1,298,000 after buying an additional 9,865 shares in the last quarter. Swiss National Bank grew its position in Establishment Labs by 1.3% during the 1st quarter. Swiss National Bank now owns 39,000 shares of the company's stock worth $1,591,000 after acquiring an additional 500 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Establishment Labs by 15.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock worth $2,196,000 after purchasing an additional 6,307 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.